Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 10/20 | 0.41 |
| ▸ | PPARA | Q07869 | 9/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.39 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175152 | 1.00 | PTGS2 (0.42) | PTGS2ITGB3ITGAVPLGPRSS1 | |
| SCHEMBL2173924 | 0.99 | ITGB3 (0.43) | PTGS2ITGB3ITGAVPLGPRSS1 | |
| SCHEMBL2173921 | 0.99 | ITGB3 (0.43) | PTGS2ITGB3ITGAVPLGPRSS1 | |
| SCHEMBL2174613 | 0.94 | ITGB3 (0.42) | PTGS2ITGB3ITGAVPLGPRSS1 | |
| SCHEMBL2173202 | 0.92 | PPARA (0.45) | PTGS2ITGB3ITGAVPPARGPPARA | |
| SCHEMBL2174476 | 0.92 | PPARA (0.45) | PTGS2ITGB3ITGAVPPARGPPARA | |
| SCHEMBL2173206 | 0.92 | PPARA (0.45) | PTGS2ITGB3ITGAVPPARGPPARA | |
| SCHEMBL2173074 | 0.91 | PTGS2 (0.44) | PTGS2ITGB3ITGAVPLGPRSS1 | |
| SCHEMBL3946797 | 0.91 | PTGS2 (0.44) | PTGS2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL2173079 | 0.91 | PTGS2 (0.44) | PTGS2ITGB3ITGAVPLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973063-B2 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-07-05 | — | — | US | claimed |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-11 | — | — | US | claimed |
| US-7626054-B2 | Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | claimed |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2008-03-20 | — | — | US | claimed |
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-17 | — | — | US | claimed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | claimed |
| US-7973063-B2 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-07-05 | — | — | US | disclosed |
| EP-1742608-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR(GAMMA) TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-11 | — | — | US | disclosed |
| US-7626054-B2 | Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-7582663-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-17 | — | — | US | disclosed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PTGS2 925/4885ITGB3 4212/4885ITGAV 3850/4885 |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PTGS2 875/4885ITGB3 4287/4885ITGAV 3868/4885 |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PTGS2 587/4885ITGB3 3913/4885ITGAV 3264/4885 |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | PPARG, PPARA, PPARD | PTGS2 452/4885ITGB3 3192/4885ITGAV 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.